Connect with us

Advocacy

Tackling the myths and misconceptions of medical cannabis

US healthcare company, Veriheal, helps us tackle misinformation around medical cannabis.

Published

on

Tackling the myths and misconceptions of medical cannabis
When it comes to cannabis we know there’s a lot of misinformation out there.

Estimated reading time: 5 minutes

Veriheal, a US healthcare company providing education and wellness resources, helps us tackle the myths and misconceptions around medical cannabis.

When it comes to cannabis we know there’s a lot of misinformation out there.

So for patients looking to explore whether cannabis could be an option for them, the internet can be a daunting place to turn to for advice. 

Veriheal is a US healthcare technology company, providing credible cannabis education and wellness resources for patients, to help make the transition a little bit easier.

 

Anthony Dutcher, chief marketing officer, Veriheal

Founded in 2017, it has helped hundreds of thousands of patients across the US connect with prescribing doctors and the firm hopes to eventually bring the platform to those in the UK.

A lot of patients visit Veriheal to address concerns and educate themselves on medical cannabis before taking the leap to access a prescription. As such, Anthony Dutcher, the company’s chief marketing officer, is no stranger to the many misconceptions people might have about starting a plant-based medicine. 

He sat down with Cannabis Health to help us tackle some of them.

 

CH: Before we start, can you give us a quick introduction to Veriheal?

Anthony: Veriheal launched September of 2017 and its entire ecosystem is rooted in patient education and advocacy. How can we put the best information out there to make the process as painless as possible? 

I think it’s important to separate Veriheal from the medical practitioners. Veriheal is the tech platform which aims to streamline the conversation between the patient and the doctor. Our customer service team can’t give medical advice, but we can get on the phone with someone and relax them as much as possible and reassure them that this is a legal medicine in their state. Veriheal is making it more readily accessible to have that conversation.

Now we’ve helped hundreds of thousands of patients across the nation, not to mention those who don’t necessarily book an appointment but through our resources, are able to access valuable information. It’s been rewarding for us just to hear these patients’ stories, to be able to facilitate that is really humbling.

 

CH: Okay, so first of all, is there enough research and evidence to be prescribing cannabis for medical conditions?

Anthony: The evidence is growing, but it’s still in its infancy and I don’t think we’ve even scratched the surface yet. It’s great to see the programmes that are now becoming available and through colleges, the doors that are opening for students to get a better understanding of cannabis – in terms of the business – as well as the chemistry of it. It also comes back to the issue of how do you supplement a study with a placebo of cannabis? It’s hard to replicate.

 

CH: Is cannabis addictive?

Anthony: I’m not a medical professional so I can’t back this up with my own research, but every report that we’ve analysed and repurposed on our blog points to no, at least in terms of the physical effects of cannabis.

 

CH: Will cannabis make me unproductive?

Anthony: Oh, the lazy stoner stigma. We’ve read plenty of reports that actually point to the opposite of that, that people are innately more active when they are taking cannabis, especially for medical reasons. We’re not talking about recreational use, although there is some overlap, but due to whatever relief the cannabis is providing, whether it’s emotional or physical in nature, the medical user is able to go about their  daily activities, without their symptoms looming over them.

 

CH: Is cannabis a gateway drug?

Anthony: People always will point to the fact that there needs to be more data and I firmly agree there needs to be way more research reported on cannabis, but with it being a schedule one drug and that research is restricted. It’s something we’re really pushing for, the intimate understanding of the chemistry of this plant and its interaction with humans and our bodies. 

We’re partnering with new agencies, as well as non-profits to make this reporting more accessible and also more accurate. The plants and products that have been analysed in some of these existing reports are not up to date with the latest products on the markets. In my professional opinion, I would say no, but we do need more research.

 

CH: What if I have a negative reaction to cannabis?

Anthony: I’m a big advocate for journaling and closely monitoring the effects, especially in the medical sector, with so many unknowns, that’s a very important element. But also, having regular follow ups with your doctor and health professionals.

The Veriheal platform carries out regular surveys and feeds back to the prescribing physicians. We also have a personalised consultation service, where patients check in with a coach who can review their daily journals and see the effects of a particular strain or terpene and cannabinoid combination. We’re ultimately looking for how we can mitigate the negative effects and increase the positive ones. 

 

CH: What advice would you give to someone considering medical cannabis but who might still be unsure?

Anthony: Definitely speak with a physician, we offer coaching sessions before you even go through the initial consultation, so patients can get a little bit more information. I would also say that self-education is key. A big reason for our success in putting peoples nerves at ease, is allowing them to review the studies and read everything we’ve written about their specific condition. Self-learning is very important as we wait for this dawning of research reporting to come and in the meantime there’s plenty of trusted resources they can turn to that are backed by the latest science.

Home » Advocacy » Tackling the myths and misconceptions of medical cannabis

Advocacy

My daughter’s seizures reduced by 95% on medical cannabis – why is it not available on the NHS?

Clover Carkeet’s family have had to fight for her to maintain access to the treatment

Published

on

My daughter’s seizures reduced by 95% on medical cannabis
Emily Carkeet with her three-year-old daughter Clover

Three-year-old Clover Carkeet’s seizures have reduced by 95 per cent with medical cannabis – so why has her family had to fight so hard to maintain access to it?

Clover had her first seizure at just 12 weeks old. Doctors diagnosed her with infantile spasms, a ‘catastrophic’ form of epilepsy that is among the most brain-damaging conditions of its kind. 

Early signs of the condition were discovered when her mum, Emily Carkeet, was 30 weeks pregnant. 

She was told that Clover was missing the part of her brain that connects the left hemisphere to the right, known in medicine as the corpus callosum. 

Seventy five per cent of newborns with the condition will grow up to live completely normal lives, but sadly Clover is among the minority that develops neurological issues from early childhood.

MyAccess clinics banner

Like many children diagnosed with rare forms of epilepsy, Clover was started on a heavy dose of steroids which she took for six weeks. 

“It was a really awful time for us,” Emily recalls. “They made her extremely poorly. She was so upset and angry. She was basically just staring into space.”

After the steroids, Clover was started on a strong antiepileptic drug called vigabatrin, with her enjoying five months without seizures. The freedom gave her the chance to develop, and even learn to crawl.

My daughter’s seizures reduced by 95% on medical cannabis

Spencer, Emily and Clover Carkeet

Trying CBD

But it wasn’t just the vigabatrin that was aiding her recovery, Emily believes. 

When Clover was four months old, her parents began giving her tiny doses of over-the-counter CBD oil called Hayleigh’s Hope. In the early days of Clover’s diagnosis, Emily had connected with hundreds of families whose children suffered from similar conditions.

“I was always searching for the answers for Clover,” Emily says. 

“I found that the children who were taking some form of CBD all seemed to be developing fairly normally. Their seizures were well controlled and they were spending less time in hospital.”

She continues: “Every time we increased her dose she would learn something new, physically her development was ahead of some of her neurotypical peers, she crawled at nine months and walked at 13 months, all these things that they said she wouldn’t do.”

But after five months Clover relapsed and developed something called focal seizures. Despite increasing her pharmaceuticals, her condition worsened until she was having as many as 100 seizures a week.

95% reduction in seizures

At this point, Emily and her partner, Clover’s father, Spencer, were at a “crossroads”. Either introduce more pharmaceutical medication or pursue a CBD prescription.

“It became abundantly clear that what we could buy over the counter just wasn’t strong enough for her,” Emily says. 

“We were at a crossroads really; we could either add more meds… but we had made a vow in those early days that that was not what we wanted for her. We wanted to give her a chance to have a quality of life, and we believed the best chance of that was by staying as far away from heavy duty drugs as possible. 

“That’s when we decided to go down the prescription route.”

Clover met criteria and was able to access a legal prescription for medical cannabis in August 2020. By November, her seizures had dropped to just three or four per week – a 95 per cent reduction. 

The following April, the family added the THC-containing oil Bedica to Clover’s course of medication, which is when the number of seizures fell “dramatically”.

“THC was the game-changer for her. She was sometimes going 10 days without a seizure,” says Emily.

“The biggest doubt for me was that THC might have detrimental behavioural and developmental effects, it worried me, but less than having her on a benzodiazepine, wired up to machines in hospital. As her mum I’ve always followed my gut instinct.”

My daughter’s seizures reduced by 95% on medical cannabis

Clover’s parents say THC was a “game-changer” for her

Battling the BPNA 

Despite Clover’s parents seeing a huge improvement in her condition and quality of life, the family faced losing her access to the medicine when her prescribing doctor was reported to the General Medical Council (GMC) last year. 

Although she doesn’t know the details of how it came about, the complaint was made shortly after Emily wrote to Clover’s neurologist in the NHS outlining her daughter’s positive response to cannabis-based medicines. 

The complaint, believed to have come from the British Paediatric Neurology Association (BPNA), centred around Clover’s age as at the time, at 17 months old, she was the youngest child in the UK to be prescribed the medicine. It stated that the doctor was not a neurologist and therefore should not be prescribing. 

BPNA guidance claims that cannabis medicines can only be prescribed in children with epilepsy by a paediatric neurologist. But this is not stated anywhere in current legislation. 

The case ended up being dismissed, with the GMC’s independent medical expert quoted during the review as saying the BNPA position is “probably not in the best interests of children”.

“Doctors sign a Hippocratic oath then they don’t do what’s best for their patients. It’s very negligent to deny these kids a medicine that clearly works for them,” says Emily.

“What I don’t understand is this necessity to throw so many drugs at them just because they’re licensed.

“In my opinion – and logic should rule here – if a child finds something that works, why would you then force them to go back and try all these other things that may be detrimental to them? I find this concept of using cannabis as a last resort absolutely crazy.”

Emily believes that the BPNA guidance on medical cannabis is part of the reason why NHS access is so limited for children with epilepsy.

“They complained about Clover and made no effort to speak to me about how she was doing at all. They don’t listen to us as parents, even though, when you’re a parent of a child with epilepsy, you become the expert on their condition,” she says.

“It’s just so wrong on so many levels.”

Emily and Spencer, with Clover, on their wedding day recently

A “constant juggling act” 

Clover is doing well developmentally and starting to communicate more as she reduces her prescription drugs, something Emily puts down to the medical cannabis. 

“I had read about neuroprotective benefits from cannabis and genuinely think that because she’s had it in her life since she was so young, it’s probably protected her brain,” she says. 

“We’ve never seen any regression from any of her seizures and I honestly think it’s the cannabis we have to thank for that.”

She attends nursery and Emily has been able to return to work. Something which has been a lifeline in funding Clover’s prescription, which currently costs around £1,000 a month. 

Emily and Spencer are able to fundraise, but still pay £600 each month out of their own pockets. Emily describes the situation as a “constant juggling act”.

“I feel an extreme pressure to be working more than I am because we have this prescription to pay for,” she says.

“The person who suffers from this is Clover because she doesn’t get as much of her mum as she needs.”

But despite their struggles, Emily feels lucky they have access to the treatment when so many families in the UK are unable to obtain a prescription even privately. 

There is currently only one paediatric neurologist prescribing for children with epilepsy in the UK, and he is not currently taking on any new patients. 

“There are so many parents who are desperately trying to get this medicine, because they see the results,” she adds.

“It’s an injustice that they can’t access it.”

 

Home » Advocacy » Tackling the myths and misconceptions of medical cannabis

Continue Reading

Advocacy

Cancer survivor reveals how medical cannabis “saved his life”

Barry Freeman swapped his pain medication for medical cannabis.

Published

on

A US cancer survivor has shared how medical cannabis helped him manage debilitating pain and stop his usage of multiple medications.

Texan cancer survivor Barry Freeman – who also suffers from PTSD – introduced medical cannabis into his treatment plan in 2019 and has since eliminated the consumption of dozens of pain pills while experiencing a drastic reduction in symptoms with no side effects.

In 2015, a time he describes as “the worst year of his life,” Barry lost his son and received a stage-four colorectal cancer diagnosis.

After being initially turned away by multiple doctors due to his terminal diagnosis, Barry underwent 37 rounds of chemotherapy and radiation treatment. He finally achieved remission in 2017 but his cancer treatment’s lasting effects combined with emotional distress led to continued symptoms of chronic pain, anxiety and panic attacks.

“I was in a very dark place that year. Living with cancer and losing my son caused severe depression on top of a barrage of physical symptoms that made my life miserable,” Barry said.

Barry then sustained a debilitating shoulder injury in 2018, exacerbating his condition and leading to a prescription of 12 pain pills per day. It was then his physician recommended medical cannabis as a treatment option.

“Medical cannabis saved my life,” he continued.

“I felt more relief than I’d ever felt through any pain pill. I could feel the calming effect of the medication come over me. I feel better than I did at 45-years-old. Emotionally and physically, it’s extraordinary to be here now and feel this way after being so sick.”

The Compassionate Use Program (CUP) was enacted by the Texas legislature in June 2015, allowing for the first legal use of medical cannabis products by patients with intractable epilepsy.

It was not until the program expanded in 2019 to include terminal cancer, all forms of epilepsy, autism, multiple sclerosis, spasticity, ALS and hundreds of neurodegenerative disorders that patients like Barry became eligible to access medical cannabis.

Following the 2021 session, the programme expanded to include all cancer patients and those suffering from PTSD.

Barry was provided with cannabis by Texas Original Compassionate Cultivation , a licensed medical cannabis producer that works across the state.

Morris Denton, CEO of the company, believes that more still needs to be done to improve access for patients in Texas.

“Barry was ineligible for life-altering medication for almost four years after his initial diagnosis,” Denton said.

“No one should have to endure a delay in treatment for symptoms that medical cannabis is proven to relieve. This is why continuing to expand the Compassionate Use Program matters.

“There are thousands of Texans who can and should be benefitting from the power of medical cannabis now and our team is dedicated to expanding the CUP to include each of them.”

Continue Reading

Advocacy

Growing “appetite” for medical cannabis among UK clinicians

Over 300 health professionals have signed up to learn more about medical cannabis.

Published

on

Growing "appetite" for medical cannabis among UK clinicians
The Medical Cannabis Clinicians Society (MCCS) now has revealed it now has over 300 members.

Over 300 health professionals have signed up to learn more about medical cannabis in the UK since 2019.

Just two and half years after its launch, the Medical Cannabis Clinicians Society (MCCS) now has revealed it now has over 300 members, as it prepares to launch a series of in-person events this year.

Over 300 clinicians, including specialist consultants in a wide range of specialisms, GPs, nurses and allied health professionals, are now active members of the society, sharing best practice, learning from each other, and accessing regular expert support. 

Bosses say this growth demonstrates the “appetite” of health professionals to learn more about this “life-changing” medicine.

Fibromyalgia: A banner advert for the medical cannabis clinic

Throughout 2022, the MCCS executive committee is planning to hold five in-person events across the UK, offering attendees a practical introduction to medical cannabis and CBD. 

The first events will take place in Manchester on Thursday 12 May and Belfast on 1 June, followed by sessions in Edinburgh, Cardiff and London before the end of the year. 

Further events are expected to take place in Liverpool, Newcastle, Bristol, Birmingham and Dublin in 2023.

Open to clinicians, medical students, scientists, researchers, professionals and patients curious about medical cannabis and the current state of prescribing, evidence and availability in the UK, the events will take place from 6.30pm for two hours, with networking and a panel Q&A for attendees following the speakers. 

Prescribing doctors from the executive committee will be joined at each event by society chair, Professor Mike Barnes, as well as medical cannabis patients.

Sativa Learning’s Ryan McCreanor and Volteface’s Katya Kowalski, will also present education opportunities and research insights. 

Professor Mike Barnes, chair of the Medical Cannabis Clinicians Society said:  “The growth we have seen in our membership over the last two and a half years demonstrates the appetite the UK’s clinicians have to learn about this life-changing medication. 

“With significant restrictions meaning that only Specialist Consultants can prescribe, little to no cannabis education for medical students, and the fact that medical cannabis is only available via privately prescribing doctors, the number of clinicians choosing to educate themselves and access support via the Society should be noted by leaders in the health service and in Government.

“Our programme of events, which will see us visit Manchester, Edinburgh, Belfast, Cardiff and London this year, and Liverpool, Newcastle, Bristol, Birmingham and Dublin in 2023, are a fantastic opportunity for clinicians and medical students particularly to learn the facts about this treatment and practical steps to prescribing.”

Hannah Deacon, executive director of the Medical Cannabis Clinicians Society, added:  “The Medical Cannabis Clinicians Society believes that everyone who could benefit from medical cannabis should have access to it. Our mission is to give clinicians access to evidence, training, expert guidance, peer support and licensed product information so they can prescribe life-changing medical cannabis treatments to all patients in the UK, on the NHS. 

“The Society is an expert-led, independent, not-for-profit community, dedicated to bringing this safe, legal and effective medicine to people living with chronic conditions.” 

The first event will take place at The Midland Hotel in Manchester at 6.30pm on Thursday 12 May. 

Dr Niraj Singh, consultant psychiatrist from The Medical Cannabis Clinics and executive committee member of the MCCS, will share his experience of becoming a medical cannabis prescriber. 

Prof Barnes will explore the history and evidence for medical cannabis.

Home » Advocacy » Tackling the myths and misconceptions of medical cannabis

Continue Reading

Trending